Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Mylan Japan Offers Severance Package for 110 Sales Reps
A Japan arm of major generic maker Mylan, Mylan Seiyaku, is offering a severance package for some 110 sales reps who will return from Pfizer Japan, the company’s partner in the generic business in the country, at the end of…
To read the full story
Related Article
- Mylan Japan Labor Union, Management Reach Settlement; All 14 Members to Leave on May 31
May 30, 2016
- Mylan Japan Management, Labor Union Remain at Odds over Sales Rep Layoff
April 21, 2016
- Mylan Japan Labor Union Raps Management over “Effective Dismissal”, No Progress Made in 1st Round of Negotiations
April 6, 2016
- Japan Units of Abbott, Mylan to Run Separate Operations for Now
March 4, 2015
- All Eyes Glued to Japan Realignment after Mylan’s Buyout of Abbott’s Established Product Biz
September 8, 2014
- Mylan Generics Will Be Distributed under Pfizer Brand Next Year: Pfizer’s Matsumori
July 17, 2013
- Pfizer-Mylan Pair’s Japan Generic Share at 2.8%, Aspire for Bigger Slice of Market
April 22, 2013
- Pfizer Confident about Joining Top 3 in Japan Generic Sales by around 2015: Unit Chief Matsumori
February 7, 2013
- Pfizer, Mylan Ink Strategic Collaboration in Japan Generics Biz; Aim for No. 3 in Market
August 24, 2012
BUSINESS
- Astellas on Track to Hit 30% Margin Goal Early after Strong H1 Scorecards
November 5, 2026
- Nxera Inks US$1.47 Billion Deal with AbbVie for IBD Drug
November 5, 2026
- Kissei Might Revise Midterm Targets as Tavneos Faces Approval Revocation
November 5, 2026
- Boehringer, Lung Cancer Society Launch 5-Year Hernexeos Real-World Study
November 5, 2026
- ASKA Snags Japan Rights to Minghui’s TED Therapy
November 5, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…